RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript

News Room
By News Room 2 Min Read

Operator

Good morning, and welcome to RAPT’s conference call. [Operator Instructions] And as a reminder, today’s call is being recorded.

I will now turn the call over to Sylvia Wheeler. You may begin.

Sylvia Wheeler

Thank you, operator, and good morning. Thank you for joining us to discuss our press release issued this morning, which is available along with accompanying slides in the Investors section of the company’s website at RAPT.com.

On the call with me today are Dr. Brian Wong, Chief Executive Officer; and Dr. Bill Ho, Chief Medical Officer, with prepared remarks; and Rodney Young, Chief Financial Officer, who will join us for the question-and-answer period. In addition, we have a special guest, Dr. Ana Maria Giménez-Arnau, Professor at the Hospital del Mar Medical Research Institute in Barcelona.

As outlined on Slide 2, we remind you that during this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors in our most recent quarterly report on Form 10-Q, which can be found on our website. While we may elect to update these forward-looking statements in the future, we specifically

Read the full article here

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *